The antimalarial ferroquine: from bench to clinic.

Abstract

Ferroquine (FQ, SSR97193) is currently the most advanced organo-metallic drug candidate and about to complete phase II clinical trials as a treatment for uncomplicated malaria. This ferrocene-containing compound is active against both chloroquine-susceptible and chloroquine-resistant Plasmodium falciparum and P. vivax strains and/or isolates. This article focuses on the discovery of FQ, its antimalarial activity, the hypothesis of its mode of action, the current absence of resistance in vitro and recent clinical trials.

• Authors: C Biot, F Nosten, L Fraisse, D Ter-Minassian, J Khalife, D Dive
• Journal: Parasite (Paris, France) (Parasite) Vol. 18 Issue 3 Pg. 207-14 (Aug 2011) ISSN: 1252-607X [Print] France
• PMID: 21894260 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Aminoquinolines
• Antimalarials
• Ferrous Compounds
• Metallocenes
• Chloroquine
• ferroquine

Topics

• Aminoquinolines (chemistry, pharmacology, therapeutic use)
• Animals
• Antimalarials (chemistry, pharmacology, therapeutic use)
• Chloroquine (chemistry, pharmacology)
• Clinical Trials, Phase II as Topic
• Drug Resistance
• Ferrous Compounds (chemistry, pharmacology, therapeutic use)
• Humans
• Malaria, Falciparum (drug therapy)
• Malaria, Vivax (drug therapy)
• Metallocenes
• Plasmodium falciparum (drug effects)
• Plasmodium vivax (drug effects)